Who are the manufacturers of zotuximab and what is their reputation?

Zolbetuximab (zolbetuximab-clzb)-VYLOY is a monoclonal antibody targeting Claudin 18.2 (CLDN18.2) developed by the Japanese pharmaceutical company Astellas Pharma. As a leading global pharmaceutical company, Astellas is known for its rigorous research and development processes and innovative drug development capabilities. It has rich experience and multiple important products in the fields of tumor immunity and medical treatment. As an innovative targeted drug that focuses on its layout, zotuximab focuses on the treatment of patients with advanced gastric cancer and gastroesophageal junction adenocarcinoma expressing CLDN18.2. Traditional therapies for these patients have limited effects and have great clinical needs.

The drug targets CLDN18.2 is a tight junction protein highly expressed on the surface of gastrointestinal tumor cells. It uses antibodies to specifically recognize and bind to tumor cells, activating the antibody-dependent cytotoxicity and complement-dependent cytotoxicity mechanisms of the immune system to achieve the purpose of accurately killing tumors. As a new type of precision targeted drug, zotuximab has demonstrated remarkable efficacy in a number of international multi-center clinical trials, promoting innovation in the treatment of gastric cancer.

In the international market, zotuximab has been approved by multiple regulatory agencies, including the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and has entered the clinical application stage. Its common specification is 100mg/bottle, and it mainly enters the Japanese and European markets through Astellas's sales network.

In the Chinese market, although zotuximab is still in the early stages of marketing, Astellas has provided strong support for the promotion of the drug with its strong influence and good brand image in the Asian market. The company continues to invest in clinical research and market education to help more doctors and patients understand the potential of CLDN18.2 targeted therapy.

Reference materials:https://www.astellas.com/en/news/29401